Literature DB >> 32748322

Alzheimer's disease pathology in a community-based sample of older adults without dementia: The MYHAT neuroimaging study.

Kevin J Sullivan1,2, Anran Liu3, Chung-Chou H Chang4, Ann D Cohen5, Brian J Lopresti6, Davneet S Minhas6, Charles M Laymon6, William E Klunk5, Howard Aizenstein5, Neelesh K Nadkarni4,7, David Loewenstein8, M Ilyas Kamboh9, Mary Ganguli5, Beth E Snitz7.   

Abstract

A true understanding of the distribution and functional correlates of Alzheimer's disease pathology in dementia-free older adults requires a population-based perspective. Here we report initial findings from a sample of 102 cognitively unimpaired participants (average age 77.2 years, 54.9% women, 13.7% APOE*4 carriers) recruited for neuroimaging from a larger representative population-based cohort participating in an ongoing longitudinal study of aging, the Monongahela-Youghiogheny Healthy Aging Team (MYHAT). All participants scored < 1.0 on the Clinical Dementia Rating (CDR) Scale, with 8 participants (7.8%) scoring CDR = 0.5. Participants completed a positron emission tomography scan using the tracers [C-11]Pittsburgh Compound-B (PiB) and [F-18]AV-1451 to estimate amyloid and tau deposition. PiB positivity was defined on a regional basis using established standardized uptake value ratio cutoffs (SUVR; cerebellar gray matter reference), with 39 participants (38.2%) determined to be PiB(+). Health history, lifestyle, and cognitive abilities were assessed cross-sectionally at the nearest annual parent MYHAT study visit. A series of adjusted regression analyses modeled cognitive performance as a function of global PiB SUVR and [F-18]AV-1451 SUVR in Braak associated regions 1, 3/4, and 5/6. In comparison to PiB(-) participants (n = 63), PiB(+) participants were older, less educated, and were more likely to be APOE*4 carriers. Global PiB SUVR was significantly correlated with [F-18]AV-1451 SUVR in all Braak-associated regions (r = .38-0.53, p < .05). In independent models, higher Global PiB SUVR and Braak 1 [F-18]AV-1451 SUVR were associated with worse performance on a semantic interference verbal memory test. Our findings suggest that brain amyloid is common in a community-based setting, and is associated with tau deposition, but both pathologies show few associations with concurrent cognitive performance in a dementia-free sample.
© 2020. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid; Neuroimaging; Population neuroscience; Tau

Mesh:

Substances:

Year:  2020        PMID: 32748322      PMCID: PMC7855234          DOI: 10.1007/s11682-020-00334-2

Source DB:  PubMed          Journal:  Brain Imaging Behav        ISSN: 1931-7557            Impact factor:   3.224


  42 in total

1.  AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure.

Authors:  Shruti Mishra; Brian A Gordon; Yi Su; Jon Christensen; Karl Friedrichsen; Kelley Jackson; Russ Hornbeck; David A Balota; Nigel J Cairns; John C Morris; Beau M Ances; Tammie L S Benzinger
Journal:  Neuroimage       Date:  2017-07-26       Impact factor: 6.556

2.  Incidence of Dementia over Three Decades in the Framingham Heart Study.

Authors:  Claudia Satizabal; Alexa S Beiser; Sudha Seshadri
Journal:  N Engl J Med       Date:  2016-07-07       Impact factor: 91.245

3.  Population Neuroscience: Dementia Epidemiology Serving Precision Medicine and Population Health.

Authors:  Mary Ganguli; Emiliano Albanese; Sudha Seshadri; David A Bennett; Constantine Lyketsos; Walter A Kukull; Ingmar Skoog; Hugh C Hendrie
Journal:  Alzheimer Dis Assoc Disord       Date:  2018 Jan-Mar       Impact factor: 2.703

4.  Meta-analysis of amyloid-cognition relations in cognitively normal older adults.

Authors:  Trey Hedden; Hwamee Oh; Alayna P Younger; Tanu A Patel
Journal:  Neurology       Date:  2013-04-02       Impact factor: 9.910

5.  Risk of progression from subjective cognitive decline to mild cognitive impairment: The role of study setting.

Authors:  Beth E Snitz; Tianxiu Wang; Yona Keich Cloonan; Erin Jacobsen; Chung-Chou H Chang; Tiffany F Hughes; M Ilyas Kamboh; Mary Ganguli
Journal:  Alzheimers Dement       Date:  2018-01-18       Impact factor: 21.566

6.  Association Between Amyloid-β, Small-vessel Disease, and Neurodegeneration Biomarker Positivity, and Progression to Mild Cognitive Impairment in Cognitively Normal Individuals.

Authors:  Neelesh K Nadkarni; Dana Tudorascu; Elizabeth Campbell; Beth E Snitz; Annie D Cohen; Edye Halligan; Chester A Mathis; Howard J Aizenstein; William E Klunk
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2019-10-04       Impact factor: 6.053

7.  Does a cognitive stress test predict progression from mild cognitive impairment to dementia equally well in clinical versus population-based settings?

Authors:  Joanne C Beer; Beth E Snitz; Chung-Chou H Chang; David A Loewenstein; Mary Ganguli
Journal:  Int Psychogeriatr       Date:  2018-01-16       Impact factor: 3.878

8.  Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition.

Authors:  Prashanthi Vemuri; Val J Lowe; David S Knopman; Matthew L Senjem; Bradley J Kemp; Christopher G Schwarz; Scott A Przybelski; Mary M Machulda; Ronald C Petersen; Clifford R Jack
Journal:  Alzheimers Dement (Amst)       Date:  2016-12-21

Review 9.  Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: A meta-analysis.

Authors:  Jenalle E Baker; Yen Ying Lim; Robert H Pietrzak; Jason Hassenstab; Peter J Snyder; Colin L Masters; Paul Maruff
Journal:  Alzheimers Dement (Amst)       Date:  2016-10-18

10.  Considerations and code for partial volume correcting [18F]-AV-1451 tau PET data.

Authors:  Suzanne L Baker; Anne Maass; William J Jagust
Journal:  Data Brief       Date:  2017-10-16
View more
  1 in total

1.  Imaging beta-amyloid (Aβ) burden in the brains of middle-aged individuals with alcohol-use disorders: a [11C]PIB PET study.

Authors:  Margaret R Flanigan; Sarah K Royse; David P Cenkner; Katelyn M Kozinski; Clara J Stoughton; Michael L Himes; Davneet S Minhas; Brian Lopresti; Meryl A Butters; Rajesh Narendran
Journal:  Transl Psychiatry       Date:  2021-05-01       Impact factor: 7.989

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.